We have five products that will launch in the next 12-18 months. We recently launched Yesintek in the immunology space -- a ...

With this approval, Biocon Biologics has enlarged its oncology portfolio in the United States, including Ogivri and Fulphila. The US sales of bevacizumab was about $2 Billion in 2023. In the US ...

The approval of Jobevne expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes Ogivri (Trastuzumab-dkst) and Fulphila (Pegfilgrastim-jmdb). The company ...

The approval of JOBEVNE expands Biocon Biologics' biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company ...

“This approval builds on our successful track record of bringing the first interchangeable insulin, SEMGLEE, the first biosimilar Trastuzumab, OGIVRI, and the first biosimilar Pegfilgrastim, FULPHILA, ...

Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, Ogivri (bTrastuzumab) and Abevmy (bBevacizumab), and facilitate the sustained access of these medications that were previously ...

The 5-year exclusive agreement provides Sandoz the rights to market these medications under BBL's brands OGIVRI and ABEVMY. Trastuzumab biosimilar OGIVRI is a cheaper version of Roche's breast ...

Notably, she was involved in a validation study leading to the successful biologics license application filing of Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab), offering her ...

Kanjinti had the lowest ASP for most of the study period. During 2 quarters, Ogivri had a lower ASP, but Kanjinti soon cut its ASP to once again have the lowest ASP, the authors found. By the ...

“With the launch of Abevmy, (bBevacizumab), we are adding another world-class biosimilar to our oncology portfolio in Canada, which includes Ogivri (Trastuzumab) and Fulphila (Pegfilgrastim ...

Through this time, I will also continue to get infusions every three weeks of a drug called Ogivri. Sometimes, breast cancer cells make too many copies of a gene called HER2. This gene then makes ...